Great talk by Dr. Dalip Sethi (Senior Scientist - Terumo BCT) @ the opening of the CAR-TCR Europe 2020 conference highlighting the many challenges associated with bringing CAR-T's from bench to bedside, both from a process and standardisation perspective.
CAR-T therapies offer the potential to revolutionise cancer treatment; however, there are many challenges associated with effectively incorporating this treatment into the healthcare system from a process perspective - some of which are highlighted below:
- METHODS: The methods used to produce CAR-T's need to be controlled, reproducible and standardised
- PROCESSES: Processes need to be flexible to effectively incorporate CAR-T's into the healthcare system
- STARTING MATERIALS: There is a great degree of variability in the starting materials used to generate CAR-T's and this may effect efficacy and long-term outcomes
- VARIABILITY: There is a great degree of variability in the apheresis protocols used to generate CAR-T's and this may effect CAR-T titres
"Automation is a current and continual need for cell and gene therapy to minimise variability associated with CAR-T development"